Combined immunoglobulin and azathioprine in multiple sclerosis

European Neurology

Volumn 39, Issue 3, 1998, Pages 178-181

  Kalanie, Hossein ^a,b   Tabatabai, Seid Shahabbedin ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Mehr Hospital Iran   (Iran)

Author keywords

Azathioprine; Immunoglobulin; Multiple sclerosis; Therapy

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENCE RISK; SCORING SYSTEM;

ADOLESCENT; ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 0031968661     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007930     Document Type: Article

References (27)

1. Van Doom PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. Neurology 1990;40:209-212.
2. Cherin P, Herson S, Wechsler B, Bletry O, Degennes C, Piette JC, Ziza JM, Godeau P: Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990;ii:116.
3. Arsura E: Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989;53:S170-179.
4. Mauro G: High-dose intravenous immunoglobulins in Guillain-Barré syndrome. Rev Neurol (Paris) 1989;145:731-732.
5. Kleyweg RP, Vander Meche FGA, Meulstee J: Treatment of Guillain-Barré syndrome with high dose gammaglobulin. Neurology 1938;38: 1639-1641.
6. NIH Consensus Conference: Intravenous immunoglobulin - prevention and treatment of disease. JAMA 1990;264:3189-3193.
7. Bansil S, Cook SD, Rohowsky-Koshan C: Multiple sclerosis: Immune mechanism and update on current therapies. Ann Neurol 1995;37(S1): S87-101.
8. Cook SD, Troiano R, Rohowsky-Kochin C, Jotkowitz A, Bierlory L, Mehta PD, Oleske J, Bansil S, Dowling C: Intravenous gamma-globulin in progressive MS. Acta Neurol Scand 1992;86:171-175.
9. Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, Noy S, Sarova-Pinhas I, Melamed E: Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:1233-1236.
10. Sorensen PS: Treatment of multiple sclerosis with IVIg: Potential effects and methodology of clinical trials. J Neurol Neurosurg Psychiatry 1994;S57:62-64.
11. Tenser RB, Hay KA, Aberg LA: Immunoglobulin G immunosuppression of multiple sclerosis. Arch Neurol 1993;50:417-420.
12. Achiron A, Gilad R, Margalit R, Gabbay U, Sarova-Pinhas I, Cohen IR, Melamed E, Lider O, Noy S, Ziv I: Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J Neurol Neurosurg Psychiatry 1994;S57:57-61.
13. Noseworthy JH, O'Brien PC, van Engelen BGM, Rodriguez M: Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry 1994;S57:11-14.
14. S52.001: Intravenous immunoglobulin in multiple sclerosis: A multicenter double-blind, placebo-controlled trial. Neurology 1996;46(2): A405-406.
15. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593.
16. Ellison GW, Myers LW: A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis. Neurology 1978;S28:132-139.
17. Hughes RAC: Immunological treatment of multiple sclerosis. Int J Neurol 1983;230:73-80.
18. Mertin J: Drug treatment of patients with multiple sclerosis; in Koetzsier JC (ed): Handbook of Clinical Neurology, vol 47, No 3. New York, Elsevier, 1985, pp 187-212.
19. Rosen JA: Prolonged azathioprine treatment of non-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1979;42:338-344.
20. Patzold U, Pocklington P: Azathioprine in MS: a three-year controlled study of its effectiveness. J Neurol 1980;223:97-119.
21. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW: The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
22. British and Dutch Multiple Sclerosis Azathioprine Trial Group: Double-masked trial of azathioprine in multiple sclerosis. Lancet 1988;ii: 179-183.
23. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RAC, McPherson K, Mertin J, Milanese C: Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338: 1051-1055.
24. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
25. Poser CM, Paty DW, Scheinberg L, McDonald IW, Davis FA, Ebers CG, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
26. Thompson AJ, Noseworthy JH: New treatment for multiple sclerosis: A clinical perspective. Curr Opin Neurol 1996;9:187-198.
27. van Engelen BGM, Miller DJ, Pavelko KD, Hommes OR, Rodriguez M: Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis. J Neurol Neurosurg Psychiatry 1994;S57:65-68.